Abstract:Trypanosoma cruzi and HIV coinfection can evolve with depression of cellular immunity and increased parasitemia. We applied quantitative PCR (qPCR) as a marker for preemptive antiparasitic treatment to avoid fatal Chagas disease reactivation and analyzed the outcome of treated cases. This mixed cross-sectional and longitudinal study included 171 Chagas disease patients, 60 coinfected with HIV. Of these 60 patients, ten showed Chagas disease reactivation, confirmed by parasites identified in the blood, cerebrospinal fluid, or tissues, 12 exhibited high parasitemia without reactivation, and 38 had low parasitemia and no reactivation. We showed, for the first time, the success of the timely introduction of benznidazole in the non-reactivated group with high levels of parasitemia detected by qPCR and the absence of parasites in reactivated cases with at least 58 days of benznidazole. All HIV+ patients with or without reactivation had a 4.0–5.1 higher chance of having parasitemia than HIV seronegative cases. A positive correlation was found between parasites and viral loads. Remarkably, treated T . cruzi/ HIV-coinfected patients had 77.3% conversion from positive to negative parasitemia compared to 19.1% of untreated patients. Additionally, untreated patients showed ~13.6 times higher Odds Ratio of having positive parasitemia in the follow-up period compared with treated patients. Treated and untreated patients showed no differences regarding the evolution of Chagas disease. The main factors associated with all-cause mortality were higher parasitemia, lower CD4 counts/μL, higher viral load, and absence of antiretroviral therapy. We recommend qPCR prospective monitoring of T . cruzi parasitemia in HIV+ coinfected patients and point out the value of pre-emptive therapy for those with high parasitemia. In parallel, early antiretroviral therapy introduction is advisable, aiming at viral load control, immune response restoration, and increasing survival. We also suggest an early antiparasitic treatment for all coinfected patients, followed by effectiveness analysis alongside antiretroviral therapy. Chagas disease, present on all continents, in HIV-infected patients with cellular immunodeficiency may lead to the multiplication of T . cruzi . Reactivation of Chagas disease is life-threatening, occurring in immunosuppressed patients and diagnosed by parasite detection in blood or tissues. Here, we employed the quantitative Polymerase Chain Reaction (qPCR) to detect the increase of parasite copies in the blood and other biological fluids. Twelve HIV-coinfected patients with increased parasitemia without reactivation and ten patients with Chagas disease reactivation were selected for antiparasitic treatment and compared with 38 HIV-coinfected untreated patients with low parasitemia. Antiparasitic treatment changed positive parasitemia to negative in 77.3% of treated patients, with or without reactivation, whereas 19% of untreated cases changed from positive to negative parasitemia, after 92 and 76 months of follow-up, respectively. Two patients with reactivation died before ten days of treatment, suggesting that the diagnosis and treatment were quite late. We recommend parasitemia monitoring by qPCR and point out the value of antiparasitic treatment to coinfected T . cruzi /HIV patients with high levels of parasites in the blood, alongside early antiretroviral introduction. We also suggest early antiparasitic treatment for all coinfected patients and the analysis of the role of benznidazole in the reduction of parasitemia and control of Chagas disease evolution.

Bimodal distributions of anti-Trypanosoma cruzi antibody levels in blood donors are associated with parasite detection and antibody waning in peripheral blood.

Deferral of blood donors who have ever stayed in a Trypanosoma cruzi endemic area: An international survey

Parasite Burden of Trypanosoma cruzi in Whole Blood and Buffy Coat Determined by Real-Time PCR in Individuals with Chronic Chagas Disease

Transcriptomic evidence of immune modulation in subjects with chronic Trypanosoma cruzi infection

Quantitative PCR as a marker for preemptive therapy and its role in therapeutic control in Trypanosoma cruzi /HIV coinfection

Humans seropositive for Trypanosoma cruzi co-infected with intestinal helminths have higher infectiousness, parasitaemia and Th2-type response in the Argentine Chaco

Characterization of Latin American migrants at risk for Trypanosoma cruzi infection in a non-endemic setting. Insights into initial evaluation of cardiac and digestive involvement

Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease

Trypanosoma cruzi antigen detection in blood to assess treatment efficacy and cure in mice models of Chagas disease

Post-therapeutic cure criterion in chronic Chagas disease using Trypanosoma cruzi chimeric proteins

Serial ‘deep-sampling’ PCR of fragmented DNA reveals the wide range of Trypanosoma cruzi burden among chronically infected hosts and allows accurate monitoring of parasite load following treatment

Anti-Trypanosoma cruzi cross-reactive antibodies detected at high rate in non-exposed individuals living in non-endemic regions: seroprevalence and association to other viral serologies

Comparative evaluation of four rapid diagnostic tests that detect human Trypanosoma cruzi- specific antibodies to support diagnosis of Chagas Disease in urban population of Argentina

Loop-Mediated Isothermal Amplification of Trypanosoma cruzi DNA for Point-of-Care Follow-Up of Anti-Parasitic Treatment of Chagas Disease

Changes in lipid abundance are associated with disease progression and treatment response in chronic Trypanosoma cruzi infection

Community-based screening of Chagas disease among Latin American migrants in a non-endemic country: an observational study

Trypanosoma-Cruzi Cross-Reactive Antibodies Longitudinal Follow-Up: A Prospective Observational Study in Hematopoietic Stem Cell Transplantation

Association between altered tryptophan metabolism, plasma aryl hydrocarbon receptor agonists, and inflammatory Chagas disease

Accuracy of chimeric proteins in the serological diagnosis of chronic chagas disease – a Phase II study

Quantifying anti-trypanosomal treatment effects in chronic indeterminate Chagas disease: an individual patient data meta-analysis of two proof of concept trials

Chagas Disease Serological Test Performance in U.S. Blood Donor Specimens